Concepedia

Yuan Li Shen

YL

56

Publications

4K

Citations

32

H-Index

1992

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Xi'an Jiaotong University

First Affiliated Hospital of Xi'an Jiaotong University

Fred Hutch Cancer Center

Yuan Li Shen is an author at United States Food and Drug Administration specializing in medicine, public health, and oncology.

ORCID

Top concepts

Publications per year

1992–2024

56

Publications

56

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

Martin H. Cohen, Yuan Li Shen, Patricia Keegan et al. · The Oncologist · 2009 · 635 citations · Full text

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Aviva C. Krauss, Xin Gao, Liang Li et al. · Clinical Cancer Research · 2018 · 315 citations · Full text

Loss of Function of the Melanocortin 2 Receptor Accessory Protein 2 Is Associated with Mammalian Obesity

Masato Asai, Shwetha Ramachandrappa, Maria Joachim et al. · Science · 2013 · 294 citations · Full text

, , +16

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang et al. · The Oncologist · 2017 · 189 citations · Full text

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Sandra J. Casak, Martha Donoghue, Lola A. Fashoyin‐Aje et al. · Clinical Cancer Research · 2020 · 170 citations

Rows per page

1–5 of 56